{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:18:25Z","timestamp":1795033105824,"version":"4.10.2"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess tolerability and efficacy of amifampridine phosphate versus placebo for symptomatic treatment of Lambert\u2013Eaton Myasthenic Syndrome (LEMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This phase 3 randomized, double-blind, placebo-controlled withdrawal trial in 26 adults with LEMS compared efficacy of amifampridine phosphate versus placebo over a 4-day period. The primary endpoints were quantitative myasthenia gravis score (QMG) and subject global impression, and the secondary endpoint was Clinical Global Impression\u2013Improvement. The exploratory endpoints were 3TUG (timed up and go) test and QMG limb domain score. All participants had been receiving amifampridine phosphate (30\u201380 mg\/d divided into 3 or 4 doses daily) in an expanded access protocol and had been titrated to the optimal dose and frequency for at least 1 week before randomization into the current study. After completion of assessments after 4 days of double-blind treatment, patients had the option to return to open-label amifampridine phosphate. The efficacy endpoints were mean changes from baseline in the various evaluation parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Amifampridine phosphate (n = 13) demonstrated significant benefit in QMG and subject global impression compared with placebo (n = 13) at 4 days. Other measures of efficacy, including Clinical Global Impression\u2013Improvement, 3TUG, and QMG limb domain score were also improved. The most common \u201cadverse events\u201d in the placebo group were muscle weakness (n = 5) and fatigue (n = 4), as expected from withdrawal of amifampridine phosphate, whereas only back pain (n = 1), pain in extremity (n = 1), and headache (n = 1) were reported in amifampridine phosphate group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This phase 3 randomized, double-blind, placebo-controlled withdrawal trial in adults with LEMS provided class I evidence of efficacy of amifampridine phosphate as symptomatic treatment in LEMS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000239","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T16:02:06Z","timestamp":1551369726000},"page":"111-119","source":"Crossref","is-referenced-by-count":27,"title":["Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS"],"prefix":"10.1097","volume":"20","author":[{"given":"Perry","family":"Shieh","sequence":"first","affiliation":[{"name":"Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khema","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Miami Miller School of Medicine, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Kohrman","sequence":"additional","affiliation":[{"name":"QPS Miami Research Associates, LLC, Miami, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin J.","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Alabama at Birmingham, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","first-page":"612","article-title":"Defect of neuromuscular conduction associated with malignant neoplasms","volume":"17","author":"Lambert","year":"1956","journal-title":"Am J Physiol."},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1996","journal-title":"N Eng J Med."},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome: a review of 50 cases","volume":"111","author":"O'Neal","year":"1988","journal-title":"Brain."},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1146::AID-MUS9>3.0.CO;2-8","article-title":"Low-dose guanidine and pyridostigmine relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome","volume":"20","author":"Oh","year":"1997","journal-title":"Muscle Nerve."},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp.46.7.684","article-title":"Novel drug of choice in Eaton-Lambert Syndrome","volume":"46","author":"Lundh","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1212\/WNL.34.10.1324","article-title":"Treatment of Lambert-Eaton syndrome; 3,4 diaminopyridine and pyridostigmine","volume":"34","author":"Lundh","year":"1984","journal-title":"Neurology."},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14656566.7.10.1323","article-title":"Available treatment options for the management of Lambert-Eaton myasthenic syndrome","volume":"7","author":"Verschuuren","year":"2006","journal-title":"Expert Opin Pharmacother."},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.1993.tb04205.x","article-title":"Practical aspects of 3,4 diaminopyridine of Lambert-Eaton myasthenic syndrome","volume":"88","author":"Lundh","year":"1993","journal-title":"Acta Neurol Scand."},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4 Diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"N Eng J Med."},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4 diaminopyridine in Lambert-Eaton myathenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology."},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4 diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double blind, placebo controlled, crossover study","volume":"86","author":"Witz","year":"2009","journal-title":"Clin Pharmacol Ther."},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4 Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle Nerve."},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpba.2006.06.007","article-title":"Stability studies of ionized ad non-ionized 3,4 diaminopyridine: hypothesis of degradation pathways ad chemical structure of degradation products","volume":"43","author":"Raust","year":"2007","journal-title":"J Pharma Biomed Anal."},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol."},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/mus.25070","article-title":"Amifampridine phosphate (Firdapse) is effective and safe in a phase 3 clinical trial in LEMS","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle Nerve."},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","article-title":"Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome","volume":"52","author":"Oh","year":"2005","journal-title":"Muscle Nerve."},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis. Recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurolgy."},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain."},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet."},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/mus.26052","article-title":"3,4 Diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia","volume":"57","author":"Sanders","year":"2018","journal-title":"Muscle Nerve."},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/135245850000600411","article-title":"The significant change for the timed 25-foot walk in the multiple sclerosis functional composite","volume":"6","author":"Kaufman","year":"2000","journal-title":"Mult Scler."},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/1352458506070768","article-title":"Clinical impact of 20% worsening on timed 25-foot walk and 9-hole Peg test in multiple sclerosis","volume":"12","author":"Kragt","year":"2006","journal-title":"Mult Scler."},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1002\/mus.26091","article-title":"3,4 Diaminopyridine in Lambert-Eaton myasthenic syndrome: concerns regarding presentation of previous studies","volume":"57","author":"Oh","year":"2018","journal-title":"Muscle Nerve."},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1002\/mus.26089","volume":"57","author":"Sanders","year":"2018","journal-title":"Muscle Nerve."},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/mus.880160704","article-title":"Primary respiratory failure as the presenting symptoms in Lambert-Eaton myasthenic syndrome","volume":"16","author":"Barr","year":"1993","journal-title":"Muscle Nerve."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201903000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:05:54Z","timestamp":1693616754000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201903000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000239","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}